Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “end.” They cliff.
Loss of exclusivity (LOE) for biologics can feel like a distant milestone—until it isn’t. One day …

Pharma’s “patent squeeze” isn’t just about patents—it’s about time.
For years, investors and policymakers have focused on the headline mechanics of drug exclusivity: the original patent, the filing date, the expiration calendar. But the real battlegr…

Patients aren’t asking “about patents.” They’re asking, “Will I be able to get my medicine?”
If you’ve spent any time around drug pricing, you’ve probably heard the same refrain: “It’s complicated.” But the real complexity isn’t in the legal filings—it…

Evergreen the brand. Beat the generic.
That’s the quiet chess match playing out across pharma—where the winner isn’t always the company with the best molecule, but the one with the best patent intelligence. If you’re a generic, biosimilar, or challenge…

Pfizer’s Keytruda, also known as pembrolizumab, received initial FDA approval on September 4, 2014, for use in treating… https://www.Drugchatter.com/chat/37536/can-you-recall-the-initial-fda-approval-year-for-keytruda/

GPT, Rosalind, and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes
The life sciences world loves a good “AI breakthrough” headline. But the real question isn’t whether models like GPT can read papers faster—it’s whether they can chang…

Patent cliffs don’t just erase revenue—they rewrite the competitive map.
Most pharma teams treat the “cliff” as a countdown. But payers don’t wait for the calendar. They plan formularies, contracting, and utilization management before the first gener…

OpenAI’s GPT-4 Meets Drug Discovery: Rosalind Just “Smashed” Patent Cliffs—And the Industry Is Feeling It
The drug patent cliff has always been a slow-motion crisis: blockbuster revenues fade, generics rush in, and pipelines—often years behind—struggle…

Predict the Attack: How to Forecast Paragraph IV Filings—and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—months before launch—when a competitor files a Paragraph IV c…

Most people think “patent life” is a fixed number. In the GCC, it’s not.
If you’re a pharma executive, investor, or in-house counsel, you already know the headline: patents have a term. But in the Gulf Cooperation Council (GCC), the real question isn’t…